Belgium-based drug developer Syndesi Therapeutics has raised €17m ($21m) in a series A round from investors including Vives Louvain Technology Fund, the university venture fund of Université catholique de Louvain (UCL).
V-Bio Ventures, an investment affiliate of research institute VIB, also backed the round, which was co-led by pharmaceutical firm Novo’s early-stage investment arm Novo Seeds and VC firm Fountain Healthcare Partners.
The round further included healthcare company Johnson & Johnson’s corporate venturing arm Johnson & Johnson Innovation – JJDC,…
